Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4271 - Pre-treatment Neutrophil Lymphocyte Ratio/Platelet Lymphocyte Ratio as surrogate markers of survival in non-metastatic head and neck cancer patients :An Observational Study

Date

11 Sep 2017

Session

Poster display session

Presenters

Vijay Agarwal

Citation

Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390

Authors

V. Agarwal1, R. Rao2, H.R. Abin3, V. Rao4, R.C. Nayar4, V. Mani2, A. Ram2, B.S. Ajaikumar1

Author affiliations

  • 1 Medical Oncology, Healthcare Global Enterprises ltd., 560027 - BANGALORE/IN
  • 2 Healthcare Global Enterprises Ltd., CARE, HCG Foundation, 560027 - BANGALORE/IN
  • 3 Clinical Pharmacology, Acharya & BM Reddy College of Pharmacy, BANGALORE/IN
  • 4 Surgical Oncology, Healthcare Global Enterprises ltd., 560027 - BANGALORE/IN
More

Resources

Abstract 4271

Background

Neutrophil lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are known to be surrogate markers of inflammation and have been shown to predict mortality in patients with heart disease and cancer. In this study, we evaluate the influence of pre-treatment NLR and PLR on overall survival in head and neck cancer patients.

Methods

In this observational correlational study, subjects with a diagnosis of non-metastatic head and neck cancer were analyzed for neutrophil-lymphocyte ratio and the platelet-lymphocyte ratio at baseline before the start of their cancer-directed therapy.

Results

In this study, 189 subjects were analyzed for neutrophil-lymphocyte ratio and platelet-lymphocyte ratio before their treatment. The mean age of the study sample was 54.5±11.8. Forty-two percent underwent surgery followed by adjuvant chemoradiation while remaining underwent concurrent chemoradiation. Neoadjuvant chemotherapy was done in 29.4% of the study population. Mean NLR was 3.4±3.13 and PLR was 12.7±8.8. ROC analysis revealed 2.23 as the cutoff for NLR and 9.49 as the cutoff for PLR. Based on these cutoffs a Kaplan-Meir analysis on overall survival showed significantly improved survival (67.5% vs 58% at their mean estimates of 52 and 36 months) in those with  2.23 (Log Rank χ2=5.3, p = 0.02). Similarly, those with  9.49 (Log Rank χ2=8.1, p = 0.005). Lower NLR also showed better disease-free survival (44 vs 33 months, Log Rank χ2=4.8, p = 0.03) and lower PLR also showed better disease-free survival (44 vs 33 months, Log Rank χ2=8.2, p = 0.004).

Conclusions

Both NLR and PLR are inflammatory biomarkers in cancer. The results from this study suggest pretreatment NLR and PLR as predictive markers of survival in non-metastatic head and neck cancer patients.

Clinical trial identification

Legal entity responsible for the study

Vijay Agarwal

Funding

HCG Foundation

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.